Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CV Sciences, Inc.CVSI · Entity 8316 | Director · Chief Operating Officer | December 27, 2019 | December 31, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CV Sciences, Inc.
Report date December 27, 2019 · Filed December 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,230,000 |
Reported balance
After 2019-12-27 transaction · row 1
1 source rowRow 1 · 2019-12-27 · Exercise / conversion · Acquired 250,000 · Balance 1,230,000 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2028-03-19 | Direct | 250,000 |
Reported balance
After 2019-12-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-27 · Exercise / conversion · Disposed 250,000 · Balance 250,000 F1: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2019 Filed Dec 31, 2019 20:27 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001510964-19-000082 · wf-form4_157782402829539.xml · derivative · entry 2 Mona Michael III · CIK 0001595068 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 20:27 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Exercise / conversionCommon Stock | 250,000 | $0.40 | $100,000.00 |
DisclosureSEC source: 0001510964-19-000082 · wf-form4_157782402829539.xml · nonDerivative · entry 1 Mona Michael III · CIK 0001595068 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2018 Filed May 9, 2018 00:27 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001683168-18-001236 · mona3.xml · derivative · entry 1 Mona Michael III · CIK 0001595068 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-03-19 F1 · derivative.underlying_shares: The stock options are fully-vested on the Date of Grant. Read SEC document |
| July 14, 2017 Filed Mar 28, 2018 12:01 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001683168-18-000771 · monaiii_f4.xml · derivative · entry 2 Mona Michael III · CIK 0001595068 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-04-06 F3 · derivative.underlying_shares: On April 7, 2017, the Reporting Person was granted an option to purchase 1,000,000 shares of the Issuer's Common Stock. The option is performance-based, and vests and becomes exercisable as follows: (i) when the Company has final meeting minutes from a pre-IND meeting as authorized by the FDA for a drug development program utilizing CBD as the active pharmaceutical ingredient (25% vesting of the shares subject to the option); (ii) when the Company is granted an IND (25% vesting of the shares subject to the option); and (iii) when the Company commences its first human dosing under the IND (50% vesting of the shares subject to the option). On July 14, 2017, the first performance criterion was met resulting in vesting of the option as to 250,000 shares. Read SEC document |
| July 14, 2017 Filed Mar 28, 2018 12:01 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001683168-18-000771 · monaiii_f4.xml · derivative · entry 1 Mona Michael III · CIK 0001595068 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2026-07-05 F1 · derivative.underlying_shares: On July 6, 2016, the Reporting Person was granted an option to purchase 4,000,000 shares of the Issuer's Common Stock. The option is performance-based, and vests and becomes exercisable as follows: (i) the first time the Issuer completes development of a U.S. Food & Drug Administration ("FDA") current good manufacturing practice grade batch of successfully synthetically formulated Cannabidiol ("CBD") for use in drug development activities (25% vesting of the shares subject to the option); (ii) when the Company has final meeting minutes from a pre-investigational new drug application ("IND") meeting as authorized by the FDA for a drug development program utilizing CBD as the active pharmaceutical ingredient (25% vesting of the shares subject to the option); (iii) when the Company is granted an IND (25% vesting of the shares subject to the option); and (iv) when the Company commences its first human dosing under the IND (25% vesting of the shares subject to the option). F2 · derivative.underlying_shares: On July 14, 2017, the second performance criterion was met resulting in vesting of the option as to 1,000,000 shares. Read SEC document |
| March 15, 2017 Filed Mar 30, 2017 20:56 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-017743 · v462986_4.xml · derivative · entry 1 Mona Michael III · CIK 0001595068 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option is fully vested on the date of grant. Read SEC document |
| October 05, 2016 Filed Oct 17, 2016 22:33 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001683168-16-000332 · monaiii_frm4.xml · derivative · entry 1 Mona Michael III · CIK 0001595068 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2026-07-05 F1 · balance_after: See remarks below. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.